One of them is demonstrated in an animal model blockage of CD73 leading to improved efficiency of anti-CTLA-4- or anti-PD1-induced antitumor activity in colon, prostate, and breast cancer subjects [47]. This evidence concerns the gene PDCD1 and breast cancer.